Kyowa Kirin (KYKOF) Stock Price, News & Analysis

Company Overview

Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, marketing, and import/export of pharmaceuticals for oncology, nephrology, central nervous system, and immunology therapeutic areas in Japan, the United States, rest of the Americas, Europe, Asia, and internationally. Its products include ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; and Romiplate/Nplate, a genetically recombinant protein that produces platelet through the stimulation of thrombopoietin receptors. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, an anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.

Key Stats

• Today's Range: $16.05 to $16.05
• 50-Day Range: $16.05 to $20.97
• 52-Week Range: $14.36 to $22.21
• Volume: 4,600 shs
• Average Volume: 2,404 shs
• Market Capitalization: N/A
• P/E Ratio: 0.47
• Dividend Yield: 124.23%
• Price Target: N/A
• Consensus Rating: N/A

Kyowa Kirin Stock Analysis - MarketRank™

Kyowa Kirin scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Kyowa Kirin.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Kyowa Kirin is 0.47, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 128.77.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kyowa Kirin is 0.47, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 105.47.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Kyowa Kirin has a short interest ratio ("days to cover") of 2232.5, which indicates bearish sentiment.

Change versus previous month

Short interest in Kyowa Kirin has recently increased by 18.25%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Kyowa Kirin pays a meaningful dividend of 1.56%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Kyowa Kirin does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Kyowa Kirin is 58.08%. This payout ratio is at a healthy, sustainable level, below 75%.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Kyowa Kirin has a short interest ratio ("days to cover") of 2232.5, which indicates bearish sentiment.

Change versus previous month

Short interest in Kyowa Kirin has recently increased by 18.25%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: 0.07

News Sentiment

Kyowa Kirin has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Kyowa Kirin this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kyowa Kirin insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 10.28% of the stock of Kyowa Kirin is held by institutions.

KYKOF Stock Analysis - Frequently Asked Questions

How have KYKOF shares performed this year?

Kyowa Kirin's stock was trading at $16.75 on January 1st, 2024. Since then, KYKOF shares have decreased by 4.2% and is now trading at $16.05.
View the best growth stocks for 2024 here.

How do I buy shares of Kyowa Kirin?

Shares of KYKOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - General
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:KYKOF
• CUSIP: N/A
• CIK: N/A
• Web: www.kyowakirin.com
• Phone: (135) 205-7200
• Fax: N/A
• Employees: 5,974
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: 0.47
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A